SOURCE: Immunovative, Inc.

Immunovative, Inc.

August 02, 2012 07:30 ET

Immunovative, Inc. Announces the Appointment of Dr. Zivile Katiliene as Director of Regulatory Affairs and Clinical Operations for Immunovative Therapies, Ltd.

NEW YORK, NY--(Marketwire - Aug 2, 2012) - Immunovative, Inc. ("IMUN") (OTCBB: IMUN) announces today the appointment of Dr. Zivile Katiliene as Director of Regulatory Affairs and Clinical Operations of Immunovative Therapies, Ltd. ("ITL"). Dr. Katiliene will be responsible for assuring compliance with FDA regulations, preparing and assuring the accuracy of regulatory submissions as well as the development of global clinical research operations including quality assurance and control programs, oversight and management of Clinical Research Organization operations, preparation of clinical study plans, data management plans and the writing of Standard Operating Procedures.

Dr. Katiliene previously worked at the University of Colorado Cancer Center where her primary responsibility was to oversee management of all clinical research to assure compliance with Federal regulations related to Good Clinical Practices (GCP), including development, maintenance and support of systems and business processes. Dr. Katiliene has a Ph.D. in chemistry and a Graduate Degree in Clinical Research Management both from Arizona State University. She also has experience in clinical research project management, medical writing, data management, and regulatory document preparation for IND submissions. She is also a certified Black Belt in Lean Six Sigma methodologies for business process improvement.

Dr. Michael Har-Noy, CEO of Immunovative Therapies, Ltd. stated: "With a decade of clinical research experience in the pharmaceutical industry and academic institutions, Dr. Katiliene has a unique blend of knowledge and experience related to the conduct of clinical trials and regulatory compliance. Her experience has spanned planning, designing and implementing clinical trials from concept to completion. She will provide ITL with oversight of many aspects of our clinical research programs, including budgeting for resources, communicating with the project teams, and establishing performance metrics to measure the impact of clinical operations. We are again pleased that our technology and clinical development programs are able to attract such high quality managers to our growing team of professionals."

About Immunovative, Inc.:
On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products.

About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative Therapies Ltd specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.

Contact Information

  • For more information please contact:

    Mr. Antonio Treminio
    Chairman & Chief Executive Officer
    Immunovative, Inc.
    New York: +1-212-315-9705
    Montreal: +1-514-840-3697
    Email: Email Contact

    Dr. Michael Har-Noy
    Founder & Chief Executive Officer
    Immunovative Therapies, Ltd.
    Israel Tel: +972-2-6506288
    US Tel: +1-760-444-9040
    Email: Email Contact